Search

Your search keyword '"Algeciras‐Schimnich, Alicia"' showing total 485 results

Search Constraints

Start Over You searched for: Author "Algeciras‐Schimnich, Alicia" Remove constraint Author: "Algeciras‐Schimnich, Alicia"
485 results on '"Algeciras‐Schimnich, Alicia"'

Search Results

1. Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

2. Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: A Report from the International CTAD Task Force

4. Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice

5. Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force

13. Association of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and Alzheimer's disease

14. CSF phosphorylated tau as an indicator of subsequent tau accumulation

15. Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study

18. Effect of cerebrovascular risk factors on the prediction of Alzheimer’s disease neuropathologic change using plasma biomarkers (N4.003)

19. Results from a Phase 2 Clinical Trial of Repeated Intrathecal Autologous Adipose-derived MSCs in ALS (S5.004)

25. Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals

26. Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology

27. Identification of Necessary Plasma Biomarkers for Prediction of Alzheimer’s Disease Neuropathologic Change

28. Trajectories of plasma biomarkers of Alzheimer’s disease and neurodegeneration in the general population

29. Plasma biomarkers of Alzheimer’s disease in a biracial, community‐based sample

30. Plasma biomarkers of Alzheimer´s disease in the continuum of dementia with Lewy bodies

31. Non‐imaging measures to predict variability in white matter changes relevant to VCID

32. Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET

33. Vascular risk, gait, behavioral, and plasma indicators of VCID

39. Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies.

40. Vascular risk, gait, behavioral, and plasma indicators of VCID.

41. Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET.

42. Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort

43. Plasma‐derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community‐based study

47. Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis.

50. Predicting amyloid PET and tau PET stages with plasma biomarkers

Catalog

Books, media, physical & digital resources